Peer-reviewed research, video abstracts, and curated reading.
Published work, curated research, and the landmark studies that shape modern kidney and metabolic nutrition science.
Featured video abstract
A visual summary of my Nutrients publication on hyperphosphatemia in kidney failure.
Source: encyclopedia.pub/video/1810
Selected publications
Nutrients
Hyperphosphatemia in Kidney Failure: Pathophysiology, Challenges, and Critical Role of Phosphorus Management
Author · May 2025
Journal of the American Society of Nephrology (JASN)
Role of Tenapanor in the Management of Hyperphosphatemia
Author · October 2025
In preparation — July 2026
The Hidden Dangers of Hyperphosphatemia in Health and Kidney Disease: Etiology, Complications, and Interventions
Lead author · 2026
In preparation — September 2026
Lupus Nephritis: Molecular Pathogenesis, Biomarkers, and Emerging Targeted Therapies in Precision Medicine
Author · 2026
Curated research
Foundational trials and clinical guidelines in kidney and metabolic care.
KDIGO 2024 Guideline
Evaluation and Management of Chronic Kidney Disease
The global reference standard for CKD care — essential reading for any patient or clinician.
NEJM
Dapagliflozin in Patients with Chronic Kidney Disease (DAPA-CKD)
Landmark trial reshaping kidney-protective therapy across diabetic and non-diabetic CKD.
NEJM
Empagliflozin in Patients with Chronic Kidney Disease (EMPA-KIDNEY)
Confirms SGLT2 benefit across a broad CKD population — practice-changing evidence.
NEJM
Finerenone in CKD and Type 2 Diabetes (FIDELIO-DKD)
A new pillar in cardiorenal protection that every CKD patient should know about.
CJASN
Healthy Dietary Patterns and Risk of Mortality and ESRD in CKD: A Meta-Analysis
Real-world evidence that plant-forward, Mediterranean-style eating slows CKD progression and reduces mortality.
KDIGO
2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Foundational for IgA nephropathy, lupus nephritis, and other immune-mediated kidney disease.
European Heart Journal
Finerenone in CKD and Type 2 Diabetes — Pooled FIDELIO-DKD & FIGARO-DKD (FIDELITY)
Pooled analysis confirming that finerenone and SGLT2 inhibitors are additive — patients benefit from both pillars, not one or the other.
NEJM
Semaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease (FLOW)
First trial proving a GLP-1 receptor agonist reduces major kidney events and cardiovascular death in CKD — reshapes the CKD treatment algorithm.
Lancet
Sparsentan in Patients with IgA Nephropathy (PROTECT)
Dual endothelin/angiotensin antagonism delivers a meaningful proteinuria reduction beyond ACE/ARB in IgAN — central to the new KDIGO IgAN pathway.
NEJM
Atrasentan in Patients with IgA Nephropathy (ALIGN)
Selective endothelin-A antagonism with a clean safety signal — another emerging option for high-risk IgAN.
NEJM
Voclosporin for Lupus Nephritis (AURORA 1)
First calcineurin inhibitor with FDA approval for active lupus nephritis — pivotal for the modern triple-therapy paradigm.
NEJM
Belimumab plus Standard Therapy for Lupus Nephritis (BLISS-LN)
Adding belimumab to standard induction improves renal response — supports KDIGO 2024 add-on therapy guidance.
Nutrients
Plant-Dominant Low-Protein Diet (PLADO) for Conservative Management of CKD
The original Kalantar-Zadeh framework paper — a flexible, plant-forward alternative to rigid low-protein prescriptions.
Kidney International
Dietary Phosphorus Intake and Mortality in Moderate CKD
Real-world evidence that higher dietary phosphorus — driven largely by inorganic phosphate additives — tracks with mortality and vascular harm in CKD.
NEJM
Tirzepatide for Obesity and Heart Failure with Preserved Ejection Fraction (SUMMIT)
Cardiometabolic precedent for tirzepatide that increasingly informs how we manage CKM-syndrome patients.
KDIGO
2024 Clinical Practice Guideline for the Management of Lupus Nephritis
The new lupus nephritis playbook — multi-target induction, voclosporin/belimumab add-on, and steroid minimization.
Turn this research into your plan
Want this evidence translated to your labs and life?
The Nutritional Blueprint is a 90-minute deep dive that maps the trials above (DAPA-CKD, EMPA-KIDNEY, FLOW, KDIGO 2024) onto your diagnosis, medications, and food preferences — with a written plan you can hand your nephrologist.